TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01023737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
Study: NCT00914017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin, 40 mg daily for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill daily for 1 year
Study: NCT04619680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: 150 mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 150 mg equivalent twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
Study: NCT01824082

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perineural infusion [continuous peripheral nerve block(s)]
Description: Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural infusion [continuous peripheral nerve block(s)]
Description: Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
Study: NCT04252703

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: Invasive cardiac catheterization, balloon angioplasty and intracoronary stenting.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Description: Invasive cardiac catheterization, balloon angioplasty and intracoronary stenting.
Study: NCT03896399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ischemic conditioning followed by esophagectomy
Description: All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
Study: NCT03918642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy
Description: Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
Study: NCT04349995

Intervention type: DEVICE
Intervention: Amplatzer PFO Occluder
Description: Percutaneous PFO closure using Amplatzer PFO Occluder
Study: NCT04814355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Description: Patients will receive 400 mg/day of celecoxib for 8 weeks.
Study: NCT05241171

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: The study participants in intervention group received feedback based on steps achieved every week (converted to average steps per day) after randomization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The study participants in intervention group received feedback based on steps achieved every week (converted to average steps per day) after randomization.
Study: NCT03997422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical Sleeve Gastrectomy (VSG)
Description: Vertical Sleeve gastrectomy will be performed using five laparoscopic ports using a 40 French Bougie as a template. If a hiatal hernia is identified it will be repaired. This practice has greatly reduced postoperative reflux disease (see human subjects protection). As VSG for patients with a BMI 30.0-34.9 kg/m2 is not covered by insurance the University hospital will cover costs for up to 24 patients.
Study: NCT00118170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02787512

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Endoscopic biliary stent insertion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent
Description: Endoscopic biliary stent insertion
Study: NCT03058458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIN201104
Description: IV or SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIN201104
Description: IV or SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIN201104
Description: IV or SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIN201104
Description: IV or SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV or SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV or SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV or SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV or SC administration
Study: NCT04347811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Death Cafe
Description: Death Cafés are a specific form of debriefing that focuses on discussing death, dying, loss, and illness. Nourishment in the form of cake is provided. These sessions may allow for reflection on distressing patient events while developing a sense of community and collaboration among hospital employees.
Study: NCT03799315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: All participants randomized to the JUST group will receive training on proper use of nicotine lozenges to aid in smoking cessation. Upon release from jail, participants will receive 2mg nicotine lozenges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: All participants randomized to the JUST group will receive one hour of in-person, individual, guideline-based smoking cessation counseling during their jail stay. Upon release from jail, they will receive four 30-minute counseling phone calls over 3 weeks. These phone calls will take place at 24 hours, day 7, day 14, and day 20.
Study: NCT03070730

Intervention type: DRUG
Group type: OTHER
Intervention: Droxidopa
Description: Droxidopa: 100 mg or 300 mg t.i.d
Study: NCT01316692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker identification and analysis
Description: Correlative studies
Study: NCT03070730

Intervention type: DRUG
Group type: OTHER
Intervention: Droxidopa
Description: Droxidopa: 100 mg or 300 mg t.i.d

Intervention type: DRUG
Group type: OTHER
Intervention: Atenolol
Description: Atenolol: 50 mg Q.D.

Intervention type: DRUG
Group type: OTHER
Intervention: Atenolol
Description: Atenolol: 50 mg Q.D.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: Placebo: t.i.d

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: Placebo: t.i.d

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: Placebo: t.i.d
Study: NCT03628469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Health Support
Description: Active listening, coaching and counselling
Study: NCT02471131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN Device implantation
Description: The implantation of the device will be done into the left atrial appendage according to the guidelines.
Study: NCT01652378

Intervention type: DRUG
Intervention: ondansetron, lidocaine
Description: Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.~Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion).

Intervention type: DRUG
Intervention: ondansetron, lidocaine
Description: Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.~Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion).
Study: NCT02778776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metfomin in tablet presentation of 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metfomin in tablet presentation of 500 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Agave inulin
Description: Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave inulin
Description: Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of agave inulin
Description: Calcinated magnesia powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of agave inulin
Description: Calcinated magnesia powder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metformin placebo
Description: Calcinated magnesia tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Metformin placebo
Description: Calcinated magnesia tablet
Study: NCT04578717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air-abrasion
Description: A clinical air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 powder for 10 sec. The operating parameters were; air pressure, 20 psi; powder particles size, 20 µm; nozzle angle, 90◦; nozzle-lesion distance, 5 mm and the internal nozzle diameter, 900 µm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air-abrasion
Description: A clinical air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 powder for 10 sec. The operating parameters were; air pressure, 20 psi; powder particles size, 20 µm; nozzle angle, 90◦; nozzle-lesion distance, 5 mm and the internal nozzle diameter, 900 µm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesive application - Etch&rinse
Description: Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light. The light intensity of curing unit was calibrated daily using curing radiometer .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesive application - Etch&rinse
Description: Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light. The light intensity of curing unit was calibrated daily using curing radiometer .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adhesive application - Self-etch
Description: The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adhesive application - Self-etch
Description: The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
Study: NCT01316692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry/tissue microarrays
Description: Correlative studies
Study: NCT02645747

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO).~RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency.
Study: NCT01800604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Self-Management Intervention #1
Description: Pain Self-Management Intervention #1 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain. Participants will be encouraged to ask questions about and discuss the information presented during the treatment sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Self-Management Intervention #2
Description: Pain Self-Management Intervention #2 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #2 will emphasize cognitive restructuring skills to replace maladaptive pain-related thoughts with adaptive and reassuring ones. These skills include being able to: (1) develop awareness of one's thoughts; (2) identify and evaluate adaptive/helpful vs. unhelpful/maladaptive thoughts; and (3) develop alternative thoughts to maladaptive thoughts that are (a) realistic, (b) accurate, (c) reassuring, and (d) facilitate positive outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Self-Management Intervention #3
Description: Pain Self-Management Intervention #3 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). In Pain Self-Management Intervention #3, subjects will relax in a comfortable position with their eyes closed and simply listen to the clinician speak. The clinician will begin the session with a hypnotic induction focusing on being aware of sensations of relaxation, followed by suggestions for decreases in pain intensity and alterations in the sensory experience of what are sometimes uncomfortable sensations so that they are more comfortable.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Self-Management Intervention #4
Description: Pain Self-Management Intervention #4 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #4 will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into a participant's belief system.
Study: NCT01680224

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Weight

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Participants will view a video on overweight and obesity
Study: NCT04743037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSMART
Description: This patient-centered and participation-focused self-management intervention will help individuals develop strategies to manage chronic conditions and support their full participation in meaningful life activities.
Study: NCT00728507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid
Description: Rifapentine:150mg tablets, dose = 300mg for subjects \<= 45kg and 450mg for those \>45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid, Rifampin, Pyrazinamide, Ethambutol
Description: Administered per standard of care for TB treatment
Study: NCT02413398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Dapagliflozin
Description: Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
Study: NCT04408092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Macrophage Colony Stimulation Factor
Description: Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Macrophage Colony Stimulation Factor
Description: Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.
Study: NCT01893723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANI guided remifentanil
Description: remifentanil administration during propofol anesthesia for laparoscopic surgery is ANI guided

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ANI blind arm
Description: remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided
Study: NCT01099410

Intervention type: PROCEDURE
Intervention: Fiberoptic bronchoscopy
Description: which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. During the procedure, portions of the lungs will be washed (lavaged) with a salt water solution, to collect the alveolar macrophages. This procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. The entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours.

Intervention type: PROCEDURE
Intervention: blood draw
Description: Blood will be collected at the enrollment visit to test the subject to exclude disorders that would make it unsafe to perform the bronchoscopy, including severe anemia, infection, or disorders of kidney or liver function.

Intervention type: PROCEDURE
Intervention: intravenous catheter
Description: An intravenous catheter is placed on the day of the bronchoscopy to permit administration of sedative medications.
Study: NCT03119376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COBPEER
Description: At the end of the online training, they can participate in the study and so peer review 1 manuscript randomly selected from our sample with our tool (COBPeer).
Study: NCT04364074

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goodbelly
Description: Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This will be followed by an observation period for 6 weeks during which the subjects will not consume Goodbelly.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To prepare the placebo, the dietitian will first heat a water bath to 80 degrees Celsius. This removes the lactobacillus plantarum 299v from the probiotic drink
Study: NCT01539525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: Motivational Interview provided by either a Nurse or Computer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview
Description: Motivational Interview provided by either a Nurse or Computer